Author

K. E. Huie

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

C. A. Cohen· 2 shared J. M. Dye· 2 shared A. Narayanan· 1 shared A. O'Neill· 1 shared A. Pustilnik· 1 shared B. A. Heinz· 1 shared B. A. Pinsky· 1 shared C. B. Plescia· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

C. A. Cohen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Ebola virus matrix protein clusters phosphatidylserine, a critical step in viral budding

M. L. Husby, S. Amiar, L. I. Prugar, E. A. David, C. B. Plescia, K. E. Huie, J. M. Brannan, J. M. Dye, E. Pienaar, R. V. Stahelin

This study shows that the Ebola virus matrix protein eVP40 clusters phosphatidylserine to promote viral budding, and that fendiline reduces this clustering, inhibiting virus production and entry.

bioRxiv · Jun 8, 2021 · PreprintMicrobiology

Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen

S. Saul, M. Karim, P.-T. Huang, L. Ghita, W. Chiu, S. Kumar, N. Bhalla, P. Leyssen, C. A. Cohen, K. E. Huie, C. Tindle, M. Sibai, B. A. Pinsky, S. Das, P. Ghosh, , S. Einav

This study identifies lapatinib, an ErbB inhibitor, as a broad-spectrum antiviral that suppresses SARS-CoV-2 and VEEV replication, inflammation, and lung injury through ErbB-mediated mechanisms.

bioRxiv · May 15, 2021Microbiology

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

K. Westendorf, S. Zentelis, L. Wang, D. Foster, P. Vaillancourt, M. Wiggin, E. Lovett, R. van der Lee, J. Hendle, A. Pustilnik, J. M. Sauder, L. Kraft, Y. Hwang, R. W. Siegel, J. Chen, , Ramamurt

This paper identifies LY-CoV1404, a potent SARS-CoV-2 neutralizing antibody effective against multiple variants, including Omicron and Delta, due to its conserved epitope and resistance to common mutations.

bioRxiv · Apr 30, 2021Immunology